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manner that sequentially eliminates them from
further testing based on their performance in a
tiered system ofassays.
The basic components of the program
involve starting with an initial sortingofchem-
icals based on currently available information.
A "Tier 1" screening battery identifies chemi-
cals with the potential to interact with the
endocrine system and a subsequent "Tier 2"
testingbatteryprovidesdose-response dataand
information on whether the endocrine
activity causes adverse effects in humans, A
fish, and wildlife. Finally, a hazard assess-
ment measures the magnitude ofa chemi- U
cal's potential threat to human and ecologi-
cal health. EDSTAC also proposed a bypass
mechanism that would allow chemicals to cir-
cumvent the screeningphaseand movedirectly
to testing or hazard assessment according to
manufacturer desires. This couldsave the man-
ufacturers time and money, particularly ifthey
already suspect that a chemical may be an
endocrine disruptor.
TestValidation
A key EDSTAC requirement is that candidate
test systems used in the endocrine disruptor
program beextensivelyvalidated to ensure they
provide relevant, reliable, reproducible data.
Thequestion boils down towhether a testdoes
what it is supposed to do and whether it is
reproducible across labs.
Validation is proving to be a monumental
task. The process involves confirming that
candidate tests can detect chemical effects of
numerous hormones, including estrogens,
antiestrogens, androgens, antiandrogens, and
thyroid and antithyroid hormones. Validation
requires reproduction ofresults in several lab-
oratories, each using dozens ofdifferent chem-
ical standards ofvarying hormonal potency to
test for both weakand stronghormonal activi-
ty. Tests also need to be validated using chem-
icals known to lack endocrine activity to the
extent that they generate false positive results.
The ultimate goal ofvalidation is to provide
researchers with reliable standardized test sys-
tems they can use to screen and evaluate
chemicals for endocrine activity
under clearly defined laboratory
conditions.
The amount of effort
required for validation is so
great that some stakeholders
are concerned that it will
overwhelm resources andconsume thescreening
and testingprogram altogether. Peterde Fur, an
affiliate associate professor of environmental
studies at Virginia Commonwealth University
in Richmond, who represents several public-sec-
tor environmental groups to EDSTAC, says,
"We don't want validation to be the enemy of
progress. We're concerned that validation could
drag on for many years [and] stand in the way
ofsetting regulatory standards that are protec-
tiveofpublichealth."
Anthony Maciorowski, a senior technical
advisor in the EPA's Office of Prevention,
Pesticides, and Toxic Substances and chair of
the agency's ad hoc Endocrine Disruption
Standardization and Validation Task Force,
which currently oversees validation efforts in
theUnitedStates, says thatalthough thesecon-
assay for females), a frog metamorphosis assay,
a fish gonadal recrudescence assay, an in utero
developmental assay, and a two-generational
mammalian reproductive toxicity study. Of
these, the first nine are to be used for Tier 1
screening; the only Tier 2 test currently being
validated isthetwo-generational toxicitystudy.
Most attention to date has focused on the
uterotrophic and Hershberger assays (both in
vivo mammalian tests)
and the HTPS, which
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cerns are understandable, the EPA must use
validated tests if it wants to gather data that
will ultimately be useful for regulatory purpos-
es and risk assessment. "I think that some of
the assays can be standardized and validated in
a reasonable time frame," he says. "And as they
come on line, we can begin [screening chemi-
cals]." The task force Maciorowski heads is
now coordinating the various groups involved
in validation and will process validation data
on eachofthecandidate tests forsubmission to
the Interagency Coordinating Committee on
the Validation ofAlternative Methods (ICC-
VAM), which will conduct the final peer
review ofthe assays and the tier system. ICC-
VAM was established in 1994 by the NIEHS
with the goal ofachieving domestic and inter-
national harmonization ofcriteria for the vali-
dation and acceptance ofalternative test meth-
ods. Maciorowski says that the current goal of
the task force is to complete Tier 1 screening
validation by 2001 and Tier 2 testing valida-
tion within two to five years. The total expect-
ed cost ofvalidation is $50 million, a figure
that some stakeholders fear may be less than
adequate.
TheProposedMethods
At this point in the validation process, 10 in
vivo and in vitro assays for both mammalian
and ecological effects have been slated for vali-
dation to be completed over the next two
years. These include the following: high
throughput prescreening (HTPS) estrogen and
androgen assays, bench method assays for
estrogen and androgen, a rodent 3-day
uterotrophic assay, a rodent 5- to 7-day
Hershberger assay, a rodent 20-day
thyroid/pubertal male assay (aswell as asimilar
is an automated robotic system initially devel-
oped by the pharmaceutical industry to screen
drugs for hormonal activity. Validation ofthe
in vitro HTPS is beingled by the EPA, where-
as validation efforts for the uterotrophic and
Hershberger assays are being coordinated by
the Paris-based Organisation for Economic
Co-operation and Development (OECD),
withwhich the United States is workingclose-
ly to coordinate mutual goals on endocrine
disruptor screening. Each of the candidate
tests poses a numberofdifficult challenges. To
begin with, even though several of the assays
have a long history of laboratory use, none
weredesignedwith the explicit intent ofevalu-
ating the endocrine activity ofa large number
of chemicals. Most environmental chemicals
are likely to haveonlyweakendocrine activity,
which raises some questions among stakehold-
ers regarding the extent to which validation
should focus on low-dose testing. "Can we get
away with testing in the parts-per-million
range orwillwe have to go to parts per trillion
and beyond?" asks de Fur. "We won't know
until weget somedata."
Anotherproblem is that none ofthese tests
have ever been performed using standardized
protocols, meaning that laboratories using
them in the past have traditionally applied
their own unique approaches. According to
Maciorowski, accommodating the new
endocrine end points and designing standard-
ized protocols will be among the most chal-
lengingaspectsofthevalidation process.
Describing somepreliminarydataobtained
from the HTPS, Maciorowski says, "Some
recent reviews indicated that it isn't 'ready for
prime time.' We've had problems with low tis-
sue inducibility and high signal-to-noise ratios,
[which make it] hard to detect chemicals with
weak estrogenic activity." The HTPS deter-
mines a chemical's estrogen and androgen
receptor binding affinity by measuring a
response called transcriptional activation,
which is proportional to the degree ofreceptor
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binding. Not surprisingly, using t
a nonpharmaccutical setting is pre
difficulties. For example, a much
ofstructural, physical, and chemi(
is likely to be encountered with ei
chemicals, which cut across all clas
cals, than in specific classes of
drugs. Also, the EPA is more con
detecting environmental compoui
potency, and the HTPS was desi1
rif highly active compounds. M,
says he is nonetheless opti-
mistic that the HTPS will find
use as a prescreening tool that
can be used to prioritize large
numbers of chemicals in a












the 15,000 chemicals produced at volumes of
10,000 pounds or greater that the EPA would
like to see screened first. The task force is cur-
rently looking to implement a so-called
"Challenge Program'" whereby 10-12 contract
laboratories will evaluate several HTPS meth-
ods and gradually weed out the ones that don't
work.
In vitro systems such as the HTPS (and
analogous bench method assays) are important,
but scientists caution that they won't be able to
provide any information about how metabo-
lism might influence receptor binding; in vivo
tests are needed to obtain this important infor-
mationi. Because the uterotrophic and
Hershberger assays have over 30 years ofuse in
the pharmaceutical industry, they are among
the first in line for inl vivo test validation. Both
tests are designed to detect hormonal activity
by evaluating changes in specific organ sys-
tems. Yhe uterotrophic assay measures changes
in uterine weight following exposure to estro-
gens by female rodents that have undergone
ovariectomy. The Hershberger assay measures
increased weight of sex glands upon exposure
to androgens in castrated male rats. Herman
Koeter, the principal administrator of the
OLC'D's test guideline
program, says that the assays "seem to be
appropriate for endocrine screening," but he
adds that standardizing the tests poses continu-
ing challenges. "We want to be sure the tests
capture chemicals with weak [hormonal] activ-
i," he says, because even weak activity can be
harmful.
Concern overAnimalWelfare
Some stakeholder sectors are concerned that
validation and testing for endocrine activity'
will increase the use ofanimals in environmien-
tal research. This concern is especiallypervasive
in Europe, where the European Centre for the
Validation of Alternative Methods (ECVAM)
is pushing the OECD to reduce the use ofani-
mals in its endocrine disruptor program.
ECVAM was created in the early 1990s by the
European Union with a mandate to coordinate
the validation of alternative methods among
the union's 15 member states. Leslie Onyon, a
coordinator for endocrine disruptor test valida-
Stokes adds that the overriding goal is to
implement tests that are more predictive than
current methods. "This is more important for
public health," he says.
RiskAssessment Issues
Public health objectives will ultimately depend
on the identification ofcandidate tests that can
be modified to fit screening goals.
Furthermore, Tier 2 tests that can provide data
tion in the OECD's Environmental adeoLuate for use in risk
Health and Safety Division, says that
because ECVAM's basic purpose is to develop
alternative test methods, it is naturally critical
ofthe OECD's use ofin vivo methods. But she
adds that the actual identification ofalternative
methods is in the early stage of development.
'There's no international agreement on how
much weight should be placed on alternative
methods, so right now countries prefer short-
term in vivo tests," she says. Onyon says that
the OECD is continuing to negotiate with
ECVAM, which she says participates fully in
all discussions regarding validation. (ECVAM
is represented on the OECD's 15-member
Validation Management Group, which is simi-
lar in function to the EPA's validation task
force.)
Alternative testing is also a concern in the
United States, especially given that ICCVAM
(which also has a mandate to develop alterna-
tive methods) is a key player in the EPA's test
validation efforts. A current question under
debate is whether to use surgically altered ani-
mals in the uterotrophic and Hershberger
assays, as opposed to using immature animals
with low hormonal activity. William Stokes,
cochair of ICCVAM and a
laboratory animal veterinary
specialist, says that the rise of
_ ~~~immature animals is prefer-
able from an animal welfare per-
spective because the animals do
not run the risk of the potential pain and distress that could result from
undergoing castration or ovariectomy.
However, the model that is ultimately used
will be the one that best performs its intended
function. Stokes emphasizes that whenever the
surgical procedures are performed, appropriate
anesthetics and analgesics are used to minimize
potential pain or distress. "One of the criteria
for acceptance [of a proposed method] is that
there's adequate consideration of reduction,
replacement, and refinement ofanimal use," he
says. "This is required by federal laws in the
United States and in other coLintries." But
assessment will also be
needed so that public health officials can set
regulatory standards that are protective ofthese
end points. In anticipation of the screening
exercise that looms ahead! industry, stakehold-
ers are adamant that Tier 1 screens that are
likely to implicate certain chemicals as poten-
tial endocrine disruptors be validated concur-
rently with Tier 2 tests that can determine
whether the effects are actually adverse.
According to Ronald Miller, a senior toxi-
cology consultant with the Environment,
Health, and Safety Division at Dow Chemical,
industry representatives remain concerned that
some chemicals could be prematurely designat-
ed as harmful and then be left hangingwithout
more complete information on health effects,
information that could reduce public alarm
and suspicion. Lynn Goldman, former
EDSTAC chair and now an adjunct professor
at the Johns Hopkins School ofPublic Health
in Baltimore, Maryland, says such industry
fears are not unreasonable. But she cautions
that there are "forces whose interest is to
make the process move as slowly as possible"-
industry, for example, will be footing the
screening bill and will therefore benefit from
any delay in the validation process. Says
Goldman, "Validation has to be sensible.
Stakeholders have to be reasonable in what
they demand because you could validate indef-
initely. But I'm optimistic about validation. I
think the tests are going to perform well. They
may not be right 100% ofthe time, but I think
they will be nearly so,' she says. The challenge
of the task force is to design a testing system
that minimizes false positive results without
holding the screening process hostage to a vali-
dation effort that goes on indefinitely. In this
respect, Maciorowski suggests that even once
the formal validation process is completed,
time and experience with the tests will gauge
their true effectiveness once the screening
process is underway.
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